A Phase 1 Single-Ascending Dose (SAD) and Multiple- Ascending Dose (MAD) Study of CNM-Au8 in Healthy Male and Female Volunteers

Trial Profile

A Phase 1 Single-Ascending Dose (SAD) and Multiple- Ascending Dose (MAD) Study of CNM-Au8 in Healthy Male and Female Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 May 2016

At a glance

  • Drugs CNM Au8 (Primary)
  • Indications Demyelinating disorders
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Clene Nanomedicine
  • Most Recent Events

    • 06 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top